Since the pharmacological properties of homodimeric and heterodimeric channels differ, heterodimerization has to be taken into account when targeting the K2P3.1 (TASK-1) channel in the treatment of cardiac arrhythmias. The gene discussed is KCNK3; the disease is cardiac rhythm disease.